Literature DB >> 15209767

The prevalence of coronary heart disease in Type 2 diabetic patients in Italy: the DAI study.

.   

Abstract

AIMS: Type 2 diabetes is associated with at least a twofold increase in risk of coronary heart disease (CHD). We aimed to estimate the prevalence of CHD in the population of Type 2 diabetics cared for by the Italian network of outpatient diabetic units.
METHODS: The DAI (Diabetes and Informatics study group, Italian Association of Diabetologists, and Italian National Institute of Health) study is a multicentre cohort study of patients with Type 2 diabetes. Patients were classified as having CHD if they had: (i) a history for hospital admission for either an acute myocardial infarction (AMI) or angina; (ii) a positive ECG for prior AMI or angina; (iii) a positive history for coronary artery bypass graft; or (iv) a positive history for percutaneous transluminal coronary angioplasty.
RESULTS: A cohort of 19 468 patients was analysed: 3157 patients had CHD. The majority of events (80%) had occurred after the diagnosis of diabetes and were considered in the CHD prevalence estimate. The prevalence of CHD, adjusted by age and sex, was 9.9%: 11.0% male and 9.0% female. Angina without AMI occurred in 1306 patients; this condition was more frequent in females while a documented AMI was more frequent in males. Therapeutic procedures were performed more frequently in males. A positive association with CHD was found for gender, age at visit, duration of diabetes, hypertension, relatives with CHD, tryglicerides and microvascular complications.
CONCLUSIONS: The prevalence of CHD in this cohort is lower than previously reported; nevertheless, patients attending the diabetic care units may not be fully representative of the general diabetic population in Italy. Revascularization is less frequent in females than in males; microvascular complications and a worse metabolic control are significantly associated with CHD.

Entities:  

Mesh:

Year:  2004        PMID: 15209767     DOI: 10.1111/j.1464-5491.2004.01230.x

Source DB:  PubMed          Journal:  Diabet Med        ISSN: 0742-3071            Impact factor:   4.359


  6 in total

1.  The role of adherence in the relationship between self-efficacy and self-management in diabetic patients undergoing CABG in Taiwan.

Authors:  Heng-Hsin Tung; Ru-Yu Lien; Jeng Wei; Daniel L Clinciu; Jyun-Yi Lee; Hui-Chuan Huang
Journal:  Heart Asia       Date:  2012-09-17

2.  Effects of off-pump coronary artery bypass grafting on clinical efficacy, cardiac function and the incidence of major adverse cardiovascular events in patients with coronary heart disease.

Authors:  Qing Ma; Jiancheng Liu; Chunbo Li; Dong Wang
Journal:  Am J Transl Res       Date:  2021-03-15       Impact factor: 4.060

3.  High prevalence of arcobacter carriage in older subjects with type 2 diabetes.

Authors:  Maria Teresa Fera; Giuseppina T Russo; Antonino Di Benedetto; Erminia La Camera; Angelo Orlando; Annalisa Giandalia; Vincenzo F Ruffa; Giulia Lanza; Valeria Lentini; Giuseppa Perdichizzi; Domenico Cucinotta
Journal:  J Biomed Biotechnol       Date:  2010-05-24

4.  Monitoring the occurrence of diabetes mellitus and its major complications: the combined use of different administrative databases.

Authors:  Stefano Brocco; Cristiana Visentin; Ugo Fedeli; Elena Schievano; Angelo Avogaro; Margherita Andretta; Francesco Avossa; Paolo Spolaore
Journal:  Cardiovasc Diabetol       Date:  2007-02-15       Impact factor: 9.951

Review 5.  Can the onset of heart failure be delayed by treating diabetic cardiomyopathy?

Authors:  Anna Marcinkiewicz; Stanisław Ostrowski; Józef Drzewoski
Journal:  Diabetol Metab Syndr       Date:  2017-04-04       Impact factor: 3.320

6.  Recurrence of cardiovascular events in patients with type 2 diabetes: epidemiology and risk factors.

Authors:  Carlo B Giorda; Angelo Avogaro; Marina Maggini; Flavia Lombardo; Edoardo Mannucci; Salvatore Turco; Stefania Spila Alegiani; Roberto Raschetti; Mario Velussi; Ele Ferrannini
Journal:  Diabetes Care       Date:  2008-09-09       Impact factor: 17.152

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.